Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes

References

• Garber AJ Abrahamson MJ Barzilay JI American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement – executive summary Endocr Pract 2013 19 3 536 557 23816937
   PubMed Web of Science ®Google Scholar
• Defronzo RA Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 2009 58 4 773 795 19336687
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Eldor R Abdul-Ghani M Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes Diabetes Care 2013 36 Suppl 2 S127 S138 23882037
   PubMed Web of Science ®Google Scholar
• Wright EEJr Stonehouse AH Cuddihy RM In support of an early polypharmacy approach to the treatment of type 2 diabetes Diabetes Obes Metab 2010 12 11 929 940 20880339
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB American Diabetes Association (ADA) European Association for the Study of Diabetes (EASD) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2012 35 6 1364 1379 22517736
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 2012 55 6 1577 1596 22526604
   PubMed Web of Science ®Google Scholar
• Handelsman Y Mechanick JI Blonde L AACE Task Force for Developing Diabetes Comprehensive Care Plan American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan Endocr Pract 2011 17 Suppl 2 1 53 21474420
   PubMed Web of Science ®Google Scholar
• Drucker DJ Incretin-based therapies: a clinical need filled by unique metabolic effects Diabetes Educ 2006 32 Suppl 2 65S 71S 16554430
   PubMed Web of Science ®Google Scholar
• Drucker DJ Enhancing the action of incretin hormones: a new whey forward? Endocrinology 2006 147 7 3171 3172 16777979
   PubMed Web of Science ®Google Scholar
• Aroda VR Henry RR Han J Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review Clin Ther 2012 34 6 1247 1258. e22 22608780
   PubMed Web of Science ®Google Scholar
• Iltz JL Baker DE Setter SM Keith Campbell R Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus Clin Ther 2006 28 5 652 665 16861088
   PubMed Web of Science ®Google Scholar
• Stonehouse A Walsh B Cuddihy R Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies Diabetes Technol Ther 2011 13 10 1063 1069 21732798
   PubMed Web of Science ®Google Scholar
• Li XC Zhuo JL Current insights and new perspectives on the roles of hyperglucagonemia in non-insulin-dependent type 2 diabetes Curr Hypertens Rep 2013 15 5 522 530 23996678
   PubMed Web of Science ®Google Scholar
• Ali MK Bullard KM Saaddine JB Cowie CC Imperatore G Gregg EW Achievement of goals in US diabetes care, 1999–2010 N Engl J Med 2013 368 17 1613 1624 23614587
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going Am J Med 2010 123 Suppl 3 S38 S48 20206731
   PubMed Web of Science ®Google Scholar
• Zinman B Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time? Am J Med 2011 124 Suppl 1 S19 S34 21194577
   PubMed Web of Science ®Google Scholar
• Garber AJ Abrahamson MJ Barzilay JI American Association of Clinical Endocrinologists AACE comprehensive diabetes management algorithm 2013 Endocr Pract 2013 19 2 327 336 23598536
   PubMed Web of Science ®Google Scholar
• Nielsen LL Young AA Parkes DG Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes Regul Pept 2004 117 2 77 88 14700743
   PubMedGoogle Scholar
• Brubaker PL Drucker DJ Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors Receptors Channels 2002 8 3–4 179 188 12529935
   PubMedGoogle Scholar
• Drucker DJ Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls Diabetes 2013 62 10 3316 3323 23818527
   PubMed Web of Science ®Google Scholar
• Nielsen LL Baron AD Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes Curr Opin Investig Drugs 2003 4 4 401 405
   Google Scholar
• DeYoung MB MacConell L Sarin V Trautmann M Herbert P Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes Diabetes Technol Ther 2011 13 11 1145 1154 21751887
   PubMed Web of Science ®Google Scholar
• Fineman M Flanagan S Taylor K Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing Clin Pharmacokinet 2011 50 1 65 74 21142268
   PubMed Web of Science ®Google Scholar
• Drucker DJ Buse JB Taylor K Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 2008 372 9645 1240 1250 18782641
   PubMed Web of Science ®Google Scholar
• Raskin P Mohan A Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial) Expert Opin Pharmacother 2010 11 13 2269 2271 20536293
   PubMed Web of Science ®Google Scholar
• Bergenstal RM Wysham C Macconell L DURATION-2 Study Group Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial Lancet 2010 376 9739 431 439 20580422
   PubMed Web of Science ®Google Scholar
• Diamant M Van Gaal L Stranks S Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial Lancet 2010 375 9733 2234 2243 20609969
   PubMed Web of Science ®Google Scholar
• Russell-Jones D Cuddihy RM Hanefeld M DURATION-4 Study Group Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study Diabetes Care 2012 35 2 252 258 22210563
   PubMed Web of Science ®Google Scholar
• Blevins T Pullman J Malloy J DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes J Clin Endocrinol Metab 2011 96 5 1301 1310 21307137
   PubMed Web of Science ®Google Scholar
• Buse JB Nauck M Forst T Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study Lancet 2013 381 9861 117 124 23141817
   PubMed Web of Science ®Google Scholar
• Buse JB Rosenstock J Sesti G LEAD-6 Study Group Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 2009 374 9683 39 47 19515413
   PubMed Web of Science ®Google Scholar
• Buse JB Drucker DJ Taylor KL DURATION-1 Study Group DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks Diabetes Care 2010 33 6 1255 1261 20215461
   PubMed Web of Science ®Google Scholar
• Taylor K Gurney K Han J Pencek R Walsh B Trautmann M Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years BMC Endocr Disord 2011 11 9 21529363
   PubMed Web of Science ®Google Scholar
• Davies M Heller S Sreenan S Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas Diabetes Care 2013 36 5 1368 1376 23275363
   PubMed Web of Science ®Google Scholar
• Inagaki N Atsumi Y Oura T Saito H Imaoka T Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study Clin Ther 2012 34 9 1892 1908. e1891 22884767
   PubMed Web of Science ®Google Scholar
• Cui YM Guo XH Zhang DM Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus J Diabetes 2013 5 2 127 135 23332026
   PubMed Web of Science ®Google Scholar
• Bergenstal RM Li Y Porter TK Weaver C Han J Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c <7%, without weight gain or hypoglycaemia, over 52 weeks Diabetes Obes Metab 2013 15 3 264 271 23078638
   PubMed Web of Science ®Google Scholar
• Wysham C Bergenstal R Malloy J DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide Diabetic Med 2011 28 6 705 714 21434995
   PubMed Web of Science ®Google Scholar
• Pencek R Blickensderfer A Li Y Brunell SC Chen S Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations Int J Clin Pract 2012 66 11 1021 1032 22925173
   PubMed Web of Science ®Google Scholar
• Alves C Batel Marques F Macedo AF A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitus and cancer Diab Res Clin Pract 2012 11 98 2 271 284
   PubMed Web of Science ®Google Scholar
• Chiquette E Toth PP Ramirez G Cobble M Chilton R Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers Vasc Health Risk Manag 2012 8 621 629 23166441
   PubMedGoogle Scholar
• Robinson LE Holt TA Rees K Randeva HS O’Hare JP Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis BMJ Open 2013 3 1 pii: e00 1986
   Web of Science ®Google Scholar
• Turton MD O’Shea D Gunn I A role for glucagon-like peptide-1 in the central regulation of feeding Nature 1996 379 6560 69 72 8538742
   PubMed Web of Science ®Google Scholar
• Flint A Kapitza C Zdravkovic M The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment Diabetes Obes Metab 2013 15 10 958 962 23551925
   PubMed Web of Science ®Google Scholar
• Tatarkiewicz K Belanger P Gu G Parkes D Roy D No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks Diabetes Obes Metab 2013 15 5 417 426 23163898
   PubMed Web of Science ®Google Scholar
• Extended-release exenatide (Bydureon) for type 2 diabetes Med Lett Drugs Ther 2012 54 1386 21 23
   Web of Science ®Google Scholar
• Butler AE Campbell-Thompson M Gurlo T Dawson DW Atkinson M Butler PC Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors Diabetes 2013 62 7 2595 2604 23524641
   PubMed Web of Science ®Google Scholar
• Bonner-Weir S In’t Veld PA Weir GC Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies Diabetes Obes Metab Epub 1 8 2014
   Web of Science ®Google Scholar
• Garg R Chen W Pendergrass M Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care Nov 2010 33 11 2349 2354
   Google Scholar
• Romley JA Goldman DP Solomon M McFadden D Peters AL Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population Diabetes Technol Ther 2012 14 10 904 911 22845701
   PubMed Web of Science ®Google Scholar
• FDA. [Homepage on the Internet] Incretin and Pancreatitis http://www.fda.com/ Accessed 10 June 2014
   Google Scholar
• EMA. [Homepage on the Internet] Pancreatitis: Incretins http://www.ema.europa.eu/ema/ Accessed 10 June 2014
   Google Scholar
• Egan AG Blind E Dunder K Pancreatic safety of incretin-based drugs – FDA and EMA assessment N Engl J Med 2014 370 9 794 797 24571751
   PubMed Web of Science ®Google Scholar
• Bulchandani D Nachnani JS Herndon B Effect of exendin (exenatide) – GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model Eur J Pharmacol 2012 691 1–3 292 296 22819704
   PubMed Web of Science ®Google Scholar
• Bjerre Knudsen L Madsen LW Andersen S Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation Endocrinology 2010 151 4 1473 1486 20203154
   PubMed Web of Science ®Google Scholar
• Fineman MS Mace KF Diamant M Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment Diabetes Obes Metab 2012 14 6 546 554 22236356
   PubMed Web of Science ®Google Scholar
• Faludi P Brodows R Burger J Ivanyi T Braun DK The effect of exenatide re-exposure on safety and efficacy Peptides 2009 30 9 1771 1774 19576255
   PubMed Web of Science ®Google Scholar
• Ridge T Moretto T Macconell L Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes Diabetes Obes Metab 2012 14 12 1097 1103 22734440
   PubMed Web of Science ®Google Scholar
• Norwood P Liutkus JF Haber H Pintilei E Boardman MK Trautmann ME Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years Clin Ther 2012 34 10 2082 2090 23031623
   PubMed Web of Science ®Google Scholar
• Polonsky WH Fisher L Hessler D Bruhn D Best JH Patient perspectives on once-weekly medications for diabetes Diabetes Obes Metab 2011 13 2 144 149 21199266
   PubMed Web of Science ®Google Scholar
• Aroda VR DeYoung MB Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes Postgrad Med 2011 123 5 228 238 21904106
   PubMed Web of Science ®Google Scholar
• Best JH Boye KS Rubin RR Cao D Kim TH Peyrot M Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily Diabet Med 2009 26 7 722 728 19573122
   PubMed Web of Science ®Google Scholar
• Secnik Boye K Matza LS Oglesby A Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes Health Qual Life Outcomes 2006 4 80 17034640
   PubMed Web of Science ®Google Scholar
• Beaudet A Palmer JL Timlin L Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK J Med Econ 2011 14 3 357 366 21563878
   PubMedGoogle Scholar
• Guillermin AL Lloyd A Best JH DeYoung MB Samyshkin Y Gaebler JA Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States J Med Econ 2012 15 4 654 663 22369345
   PubMedGoogle Scholar
• Samyshkin Y Guillermin AL Best JH Brunell SC Lloyd A Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US J Med Econ 2012 15 Suppl 2 6 13 22793669
   PubMedGoogle Scholar
• Buse JB Bergenstal RM Glass LC Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial Ann Intern Med 2011 154 2 103 112 21138825
   PubMed Web of Science ®Google Scholar
• Arnolds S Dellweg S Clair J Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study Diabetes Care 2010 33 7 1509 1515 20357372
   PubMed Web of Science ®Google Scholar
• Li CJ Li J Zhang QM Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity Cardiovasc Diabetol 2012 11 142 23153177
   PubMed Web of Science ®Google Scholar
• Riddle MC Forst T Aronson R Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1) Diabetes Care 2013 36 9 2497 2503 23564915
   PubMed Web of Science ®Google Scholar
• Henry RR Rosenstock J Logan DK Alessi TR Luskey K Baron MA Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes Diabetes Care 2013 36 9 2559 2565 23645886
   PubMed Web of Science ®Google Scholar